Analysts’ Recent Ratings Updates for Lexicon Pharmaceuticals (LXRX)

Several brokerages have updated their recommendations and price targets on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) in the last few weeks:

• 3/12/2025 – Lexicon Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/7/2025 – Lexicon Pharmaceuticals had its price target lowered by analysts at Piper Sandler from $10.00 to $6.00. They now have an “overweight” rating on the stock.
• 3/5/2025 – Lexicon Pharmaceuticals was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 3/4/2025 – Lexicon Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $2.00.
• 3/3/2025 – Lexicon Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 3/3/2025 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
• 1/29/2025 – Lexicon Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/29/2025 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.

Lexicon Pharmaceuticals Stock Up 1.0 %

Shares of Lexicon Pharmaceuticals stock opened at $0.36 on Wednesday. The company has a market cap of $88.25 million, a P/E ratio of -0.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals, Inc. has a one year low of $0.28 and a one year high of $2.83. The firm has a fifty day moving average of $0.71 and a two-hundred day moving average of $1.11.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. The company had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. On average, analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Bayesian Capital Management LP acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $31,000. RPO LLC purchased a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Renaissance Technologies LLC purchased a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $38,000. Arizona State Retirement System raised its holdings in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 24,615 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.